Alexion Pharma (ALXN $66.70 -3.33) announced that Soliris has been
approved by FDA for all patients with Atypical Hemolytic Uremic Syndrome (69.01
+1.64) Co announced that the FDA has approved Soliris for the treatment of all
pediatric and adult patients with atypical hemolytic uremic syndrome.
The FDA approval of Soliris in aHUS is based on data from two prospective
pivotal Phase 2 open-label clinical trials in adolescent and adult patients with
aHUS, and a third retrospective study in children, adolescents, and adults with
aHUS.






